Product logins

Find logins to all Clarivate products below.


Allergic Rhinitis | Treatment Algorithms: Claims Data Analysis | US | 2019

Allergic rhinitis is a chronic immunoglobulin E-mediated respiratory response to environmental allergens. It is typically treated with intranasal corticosteroids, followed by antihistamines, mast cell stabilizers, decongestants, leukotriene antagonists, and/or anticholinergics. Allergen immunotherapy can target specific environmental allergies and work to change the response of the patient’s immune system to the allergen. The biological therapies that target circulating free IgE, such as Xolair, may be a promising novel approach to treating the disease. The availability of allergen immunotherapy and the potential of biological therapies with novel mechanisms of action are expanding physicians’ treatment arsenal and fueling competition in the allergic rhinitis therapy market.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed allergic rhinitis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed allergic rhinitis patients?
  • How have allergen immunotherapies and/or biologics been integrated into the treatment algorithm, and what is their source of business?
  • What percentage of allergic rhinitis patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of allergic rhinitis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Renal Anemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Renal Anemia (US)
Renal anemia is a common complication of chronic kidney disease (CKD). When kidneys are diseased or impaired, they fail to generate enough EPO, causing renal anemia. The primary goal of renal…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
Report
Systemic Lupus Erythematosus – Landscape & Forecast – Disease Landscape & Forecast (G7)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment can be highly…